Dance of the RNases: coordinating the removal of RNA-DNA hybrids
Mainz, 27 November 2019. Two research teams led by Professors Brian Luke and Helle Ulrich at the Institute of Molecular Biology have deciphered how two enzymes, RNase H2 and RNase H1, are coordinated to remove RNA-DNA hybrid structures from chromosomes.
RNA-DNA hybrids are important for promoting normal cell activities like gene regulation and DNA repair, but having too many is also a risk for DNA damage and can lead to neurodegenerative disease and cancer. In their article, which was published today in Cell Reports, Brian and Helle show that the enzyme RNase H2 removes RNA-DNA hybrids primarily after DNA replication. Any remaining RNA-DNA structures are then removed by RNase H1, which acts independently of cell cycling.
DNA is normally found as a stable, double-stranded structure. However, DNA also sometimes interacts with RNA to form RNA-DNA hybrid structures that regulate gene expression and DNA repair. R-loops are a special type of RNA-DNA hybrid in which an RNA strand binds to one strand of a DNA molecule and pushes out the other DNA strand so that it is exposed as a single-stranded loop. R-loops can regulate gene activity, but also quickly become dangerous because incorrect removal can damage the DNA, potentially causing mutations. Therefore, excess R-loop formation can be toxic for cells – indeed, mutations in R-loop removal proteins are known to contribute to neuroinflammatory diseases and cancer.
R-loop removal is catalysed by the enzymes RNase H1 and RNase H2, which degrade the RNA strand. In addition, RNase H2 also has a secondary ability to excise single ribonucleotides, which can sometimes be mistakenly incorporated into DNA by polymerases in a process known as ribonucleotide excision repair (RER). Previous studies showed that mutation of RNase H2 disrupted genome stability more than RNase H1 mutation, suggesting that RNase H2 has a more important role in maintaining genome stability. However, it was never fully understood how these important enzymes are coordinated.
To dissect the distinct roles of RNase H1 and H2 in R-loop removal, the Luke lab engineered yeast to express RNase H1 and H2 only during specific phases of the cell cycle and then exposed them to methyl methanesulfonate (MMS), an agent that increases R-loop formation. Only yeast that could effectively remove R-loops would survive, while those with impaired R-loop removal would not survive.
With support from the Ulrich lab, they found that yeast expressing RNase H2 exclusively during G2 (the ‘growth phase’ of the cell cycle following DNA replication) were resistant to MMS, whereas yeast expressing RNase H2 only during S phase (the DNA replication phase) were more sensitive. This suggested that RNase H2 primarily acts to process R-loops during G2. In contrast, yeast expressing RNase H1 in either G2 or S phase were both able to survive in MMS. Surprisingly, RNase H2 expression in S phase actually induced more DNA damage, which required a special type of DNA repair called homologous recombination to fix. This pathway was not previously known to act during S phase. Therefore, this study may have revealed an unexplored repair pathway which counters damage caused by RNase H2 activity during DNA replication.
These results may explain why cells have evolved two different RNAse H enzymes. Brian Luke clarifies: “We think that RNase H2 is the ‘housekeeping’ enzyme that repairs the majority of RNA-DNA hybrids, but it is strictly regulated by cell cycling and acts only in G2 phase, or after DNA replication.” Brian and Helle speculate this may be because the additional RER activity of RNase H2 creates nicks in the DNA, which are a risk for double-strand breaks during DNA replication in S phase. Therefore, cells may have also evolved a secondary enzyme, RNase H1, which does not have RER activity and can act in all phases of the cell cycle, including S phase.
These findings help us to further understand how cells repair DNA damage associated with RNA-DNA hybrids and how impairment of this process contributes to disease.
Further information can be found here: https://www.cell.com/cell-reports/fulltext/S2211-1247(19)31441-X
S restricted expression and G2/M restricted expression
Brian Luke is an Adjunct Director at IMB and a Professor of Biology at Johannes Gutenberg University Mainz. Helle Ulrich is the Executive and Scientific Director at IMB and a Professor of Biology at Johannes Gutenberg University Mainz. Further information about research in Luke and Ulrich labs can be found at https://www.imb.de/research/luke/research/ and https://www.imb.de/research/ulrich/.
About the Institute of Molecular Biology gGmbH
The Institute of Molecular Biology gGmbH (IMB) is a centre of excellence in the life sciences that was established in 2011 on the campus of Johannes Gutenberg University Mainz (JGU). Research at IMB focuses on three cutting-edge areas: epigenetics, developmental biology, and genome stability. The Institute is a prime example of successful collaboration between a private foundation and government: The Boehringer Ingelheim Foundation has committed 154 million euros to be disbursed from 2009 until 2027 to cover the operating costs of research at IMB. The State of Rhineland-Palatinate has provided approximately 50 million euros for the construction of a state-of-the-art building and will give further 52 million in core funding from 2020 until 2027. For more information about IMB, please visit: https://www.imb.de/.
About Johannes Gutenberg University Mainz
Johannes Gutenberg University Mainz (JGU) is a globally recognized research-driven university with around 31,500 students. Its main core research areas are in particle and hadron physics, the materials sciences, and translational medicine, while its most outstanding research achievements in the humanities have been attained in the fields of American Studies and Historical Cultural Studies. JGU’s academic excellence is reflected in its success in the Excellence Initiative of the German federal and state governments: In 2012, the university’s Precision Physics, Fundamental Interactions and Structure of Matter (PRISMA) Cluster of Excellence was approved and the funding of its Materials Science in Mainz (MAINZ) Graduate School of Excellence was extended. Moreover, excellent placings in national and international rankings, as well as numerous other honors and awards, demonstrate just how successful Mainz-based researchers and academics are. Further information at https://www.uni-mainz.de/eng/.
Boehringer Ingelheim Foundation
The Boehringer Ingelheim Foundation is an independent, non-profit organization committed to the promotion of the medical, biological, chemical, and pharmaceutical sciences. It was established in 1977 by Hubertus Liebrecht (1931–1991), a member of the shareholder family of the company Boehringer Ingelheim. With the Perspectives Programme “Plus 3” and the Exploration Grants, the foundation supports independent junior group leaders. It also endows the internationally renowned Heinrich Wieland Prize as well as awards for up-and-coming scientists. In addition, the Foundation is donating a total of 154 million euros from 2009 to 2027 to the University of Mainz for the Institute of Molecular Biology (IMB). Since 2013, the Foundation has been providing a further 50 million euros for the development of the life sciences at the University of Mainz. https://www.boehringer-ingelheim-stiftung.de/en/index.html.
Press contact for further information
Dr Ralf Dahm, Director of Scientific Management
Institute of Molecular Biology gGmbH (IMB), Ackermannweg 4, 55128 Mainz, Germany Phone: +49 (0) 6131 39 21455, Fax: +49 (0) 6131 39 21421, Email: email@example.com